temferon
Cell therapyexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 5, 2019 (NCT03866109)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06716853 | Phase 1/Phase 2 (Phase 2) | Oct 22, 2024 | Alira Health, Arithmos srl, Genenta Science S.R.L., Vita-Salute University of Milano. Italy |
| NCT03875495 | Phase 1/Phase 2 (Phase 2) | Mar 6, 2019 | Genenta Science S.R.L., Vita-Salute University of Milano. Italy |
| NCT03866109 | Phase 1/Phase 2 (Phase 2) | Mar 5, 2019 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Genenta Science S.R.L. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genenta Science S.R.L. | For profit | 3 | 3 | 1 | 2019 |
| Vita-Salute University of Milano. Italy | Academic/Hospital | 2 | 0 | 1 | 2019 |
| Alira Health | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Arithmos srl | For profit | 1 | 0 | 1 | 2024 |
| Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Academic/Hospital | 1 | 0 | 1 | 2019 |
5 organizations
Page 1 / 1